Skip to main content
Harry Yoon, MD, Oncology, Rochester, MN

Harry Yoon MD MHS

Oncology•Rochester, MN

Gastrointestinal Cancer, Hematologic Oncology

Mayo Clinic

Join to view full profile

  • 200 1st Street SWRochester, MN 55905

Dr. Yoon is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Yoon's full profileAlready have an account?

Summary

  • I am a board-certified medical oncologist with a clinical specialization in GI cancers and cancers of unknown primary (CUP) My research focuses on clinical trials of novel agents and translational investigations in gastroesophageal and colorectal cancer and in CUP.

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2004 - 2008
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
  • Yale School of Medicine
    Yale School of MedicineClass of 2001
  • Johns Hopkins University Schools of Medicine and Public Health
    Johns Hopkins University Schools of Medicine and Public HealthMHS, Clinical Investigation

Certifications & Licensure

  • MN State Medical License
    MN State Medical License 2008 - 2027
  • MD State Medical License
    MD State Medical License 2004 - 2009
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Centricity Enterprise (CE), GE Healthcare, 2014-2017
  • CMS Meaningful Use Stage 2 Certification Mayo Clinic Incorporate Lab Results, Mayo Clinic, 2014-2017
  • CMS Meaningful Use Stage 1 Certification Centricity Patient Online, GE Healthcare, 2014-2017

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Tislelizumab plus chemotherapy as first-line treatment for unresectable, locally advanced recurrent/metastatic esophageal squamous cell carcinoma. 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
  • From Standardization to Personalized Care: How to Use Molecular Diagnostics to Guide Treatment 
    ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
  • CD3+ and CD8+ tumor-infiltrating lymphocyte (TIL) densities to prognostically stratify DNA mismatch repair-deficient (dMMR) colon cancer patients (pts): NCCTG N0147 (A... 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Authored Content

  • How Immunotherapy Is Transforming GI Cancer TreatmentJanuary 2019

Press Mentions

  • NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
    NCCN Clinical Practice Guidelines in Oncology: 2025 UpdatesMay 15th, 2025
  • Adding PD-1 Inhibitor to Chemoradiation Boosts Complete Response in Resectable Esophageal Cancer
    Adding PD-1 Inhibitor to Chemoradiation Boosts Complete Response in Resectable Esophageal CancerJanuary 27th, 2025
  • Neoadjuvant Chemoradiation plus Immunotherapy Boosts Responses in Esophageal Cancer
    Neoadjuvant Chemoradiation plus Immunotherapy Boosts Responses in Esophageal CancerJanuary 24th, 2025

Grant Support

  • Serial immunotherapy combination to modulate the tumor environment in patients with metastatic gastroesophageal cancerMAYO CLINIC ROCHESTER2021–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Harry Yoon, Dr. Harry Yoon, MD, Dr. H Yoon